The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial

Axicabtagene ciloleucel (axi-cel) was found to have superior clinical outcomes compared to standard of care (SOC; salvage chemoimmunotherapy, followed by high-dose therapy with autologous stem cell rescue for responders) for second-line large B-cell lymphoma (2L LBCL) in the pivotal ZUMA-7 trial. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Perales, Miguel-Angel, Kuruvilla, John, Snider, Julia Thornton, Vadgama, Sachin, Blissett, Rob, El-Moustaid, Fadoua, Smith, Nathaniel J., Patel, Anik R., Johnston, Patrick B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314822/
https://www.ncbi.nlm.nih.gov/pubmed/35970302
http://dx.doi.org/10.1016/j.jtct.2022.08.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314822/
https://www.ncbi.nlm.nih.gov/pubmed/35970302
http://dx.doi.org/10.1016/j.jtct.2022.08.010

Ejemplares similares